Presenters
Program leader
Prof. Merlin Thomas, MD
Course Details
The aim of this webinar to provide updates on treatment guidelines for patients with T2D with uncontrolled HbA1c, as well as to highlight the importance of early intensification of therapy to prevent the clinical inertia of type 2 diabetes supported by the clinical trials of linagliptin, empagliflozin and the combination empagliflozin + linagliptin.
A Match Made to Last: The Merits of a DPP4i + SGLT2i Combination in T2D Care Course Outline
- Latest guidelines in type 2 diabetes mellitus management and the importance of early intensive therapy
- Evidences to support early intensive therapy with the combination empagliflozin and linagliptin
- To discuss the clinical trial data on the cardio-renal-metabolic benefits of each individual components, Empagliflozin and Linagliptin, with overview discussion on on-going clinical trials exploring potential extended benefits of these
- Course Evaluation